Holen Sie sich die Stockscreener-App
128.75
5.71%
-7.80
Handel nachbörslich:
128.75
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know - Zacks Investment Research
Protagonist Therapeutics (PTGX) Could Be 21% Undervalued As Royalty Funded Narrative Builds - Simply Wall Street
Protagonist Therapeutics (NASDAQ:PTGX) Raised to "Strong-Buy" at UBS Group - MarketBeat
UBS sets USD 184.00 target for Protagonist Therapeutics stock - ad-hoc-news.de
UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target - Moomoo
Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology - Seeking Alpha
Protagonist Therapeutics (NASDAQ:PTGX) Stock Keeps "Outperform" Rating at Leerink Partners - MarketBeat
UBS initiates Protagonist Therapeutics stock with buy rating on drug potential - Investing.com
Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Cut to "Buy" at Wall Street Zen - MarketBeat
Protagonist Therapeutics, Inc. (PTGX) Stock forecasts - Yahoo Finance UK
Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo Finance
Protagonist Therapeutics, Inc. (PTGX) Options Chain - Yahoo! Finance Canada
Protagonist Therapeutics, Inc. (PTGX) Options Chain - Yahoo! Finance Canada
Protagonist Therapeutics, Inc. (PTGX) options chain - Yahoo Finance Australia
Protagonist Therapeutics(PTGX.US) Officer Sells US$8.31 Million in Common Stock - Moomoo
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells 58,629 Shares of Company Stock - MarketBeat
After exercising options, Protagonist Therapeutics (PTGX) CFO sells 58,629 shares under a trading plan. - stocktitan.net
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Has Consensus Price Target of $147.13 According to Analysts - MarketBeat
Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo Finance
Form 144 PROTAGONIST THERAPEUTICS For: 1 October By Investing.com - Investing.com Nigeria
Officer Asif Ali plans to sell 58,629 Protagonist Therapeutics (PTGX) shares. - Stock Titan
Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today - Benzinga
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap UpWhat's Next? - MarketBeat
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Protagonist Therapeutics (Nasdaq:PTGX)Stock Analysis - simplywall.st
1,324,498 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Bank of America Corp DE - MarketBeat
PTGX: Protagonist Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Protagonist Therapeutics (NASDAQ:PTGX) Combines High Growth Momentum With a Breakout Setup - ChartMill
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 11,200 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
(PTGX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Protagonist Therapeutics CEO sells $18.2m in shares By Investing.com - Investing.com Australia
Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC Filing - Yahoo Finance
Dinesh Ph Patel Sells 63,548 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 54,174 Shares - MarketBeat
Protagonist Therapeutics CEO sells $18.2m in shares - Investing.com India
Protagonist Therapeutics CEO sells $18.2m in shares By Investing.com - Investing.com UK
Protagonist Therapeutics (PTGX) CEO sells 125K shares in preset plan - Stock Titan
Protagonist Therapeutics(PTGX.US) Officer Sells US$18.24 Million in Common Stock - Moomoo
Protagonist Therapeutics at Cantor conference: cash, launches and pipeline By Investing.com - Investing.com Nigeria
Protagonist Therapeutics at Cantor conference: cash, launches and pipeline By Investing.com - Investing.com UK
Protagonist Therapeutics, Inc. at Citi Biopharma Back to School Summit Transcript - GuruFocus
Transcript : Protagonist Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Protagonist Therapeutics authorizes $300 million buyback plan By Investing.com - Investing.com Nigeria
Protagonist Therapeutics authorizes $300 million buyback plan By Investing.com - Investing.com South Africa
Protagonist Therapeutics (PTGX) CEO gifts stock to family - Stock Titan
Protagonist Therapeutics authorizes $300 million buyback plan - investing.com
Protagonist Therapeutics Announces $300 Million Share Repurchase Program - ACCESS Newswire
Protagonist Therapeutics Announces $300 Million Share Repurchase Program - chronicle-tribune.com
Protagonist Therapeutics Announces $300 Million Share Repurchase Program - marketscreener.com
3.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):